Johnson & Johnson Given Control of Emergent BioSolutions Factory That Botched Its Coronavirus Vaccine
The U.S. government has given Johnson & Johnson (NYSE: JNJ) control of a Baltimore production facility operated by Emergent BioSolutions (NYSE: EBS).
The move is the latest development in a controversy over Emergent's production of Johnson & Johnson's coronavirus vaccine, the latest of three to receive Emergency Use Authorization from the Food and Drug Administration. Last week, Emergent admitted that it manufactured a batch of the vaccine in the Baltimore facility that "did not meet specifications and our rigorous quality standards."
Image source: Getty Images.
Source Fool.com